Summary.-The evolution of metastatic colorectal cancer in patients who have had surgical treatment for a primary lesion was studied in relation to the progressive changes in the blood levels of carcinoenmbryonic antigen (CEA), y glutamyl transpeptidase (GGT) and routine liver function tests (LFTs). Involvement of the liver could often be reliably predicted many weeks in advance of clinical diagnosis while metastases to other sites were less likely to be detected early by this test. The association of the extent of disease with the patterns of biochemical changes is discussed with reference to several illustrative examples.
PRELIMINARY studies of the levels of carcinoembryonic antigen (CEA) in the various stages of colorectal cancer indicate that conisiderable elevations often accompany hepatic metastases Alackay et al., 1974) and serial measuremeents of CEA may raise the suspicioIn of metastases many months ahead of the clinical confirmation (Sorkin et al., 1974; Mlackay et al., 1974) . On the other hand, there is a large amount of experience of the usefulness of liver ftunction tests (LFTs) as a guide to the diagnosis of hepatic metastases. It (Aronsein, Nosslin and Phil, 1970) an(d to group patients accordinig to the extent of their hepatic metastases (Stilmant et al., 1971) . These analyses also provide an estimate of the relative contribution of the various components in a complex series of liver function tests to discriminate one disease from another. Our initial investigations have suggested that there may be advantages in combining the measurement of CEA with simultaneous measurements in gamma glutamyl transpeptidase (GGT); this combination appears to aid the discrimination of several of the different states encountered in colorectal cancer.
We have now extended this study by making observations oIn the changes of CEA and of certain serum enzymes during the evolution of metastases from colorectal cancer, and on the pattern of these measurements in post-operative cancer-free patients. The object of this studvy was to compare the results of these various tests with a view to devisinlg a sensitive system for the earlier detectioii of metastases and monitoriing their response to therapy. (Skarin et al., 1974) .
Other than the measurement of the enzyme and CEA levels, these patients have not been subjected to any special investigations apart from those requested by the surgeons. Liver scintiscans have been made only when there were clinical reasons for ordering the test. The frequency of outpatient visits was determined by the surgeon in charge; whenever possible the screening tests were made at 6-monthly intervals and at any intervening visits to hospital. The diagnosis of metastases during surveillance was based on routine examination by skilled clinicians and, with one exception of hepatomegaly which eventually was shown to be due to metastases, the subsequent evolution of the disease showed that their diagnoses were correct.
The assay of CEA was as described by Laurence et al. (1972) , the upper limit of normal being 12-5 ng/ml in our laboratory. GGT was measured as described previously .
Alkaline phosphatase was determined by the p-nitrophenylphosphate method of Bessey, Lowry and Brock (1946) . Leucine aminopeptidase was determined by the method of Willig et al. (1967) with L-leucine-p-nitroanilide as substrate.
RESULTS
The rates of increase of CEA in patients with hepatic metastases are shown in Fig. 1 . In some patients the diagnosis was established at laparotomy, in others during the surveillance. The rates of change of GGT in these patients are shown in Fig. 2 . It will be seen that both CEA and GGT can be raised considerably for several weeks before the confirmation of the diagnosis clinically. Both these measurements tend to increase progressively as the amount of tumour tissue in the liver expands. Serum alkaline phosphatase and leucine (Fig. 3) .
A.H.: A 78-year old male presented with blood loss per rectum and a mass in the right iliac fossa. The pre-operative liver function tests were within normal limits: bilirubin 0.1 mg/100 ml, AP 56 i.u./l, SGOT 8 i.u./l, SPGT 4 i.u./l. In November 1972 he had a sigmoid colectomy for a Dukes' C carcinoma which was considered to be a successful resection. Surveillance was commenced 25 weeks after resection at which time his CEA was 110 ng/ml, but the GGT and LAP were within normal limits. Both the CEA and GGT showed a near exponential rise. Hepatic metastases were confirmed by liver scintiscan 30 weeks after starting the surveillance. Routine LFTs at this time showed a bilirubin of 0-2 mg/100 ml, AP 346 i.u./l, SGOT 22 i.u./l and SGPT 8 i.u./l (Fig. 4) . H.M.: A 56-year old female underwent an extended hemicolectomy for a Dukes' C2 carcinoma of the splenic flexure in November 1972. Surveillance began 6 weeks after surgery, since when there has been a slow increase of GGT. In November 1973 she was unwell, anaemic, the ESR was raised and vague shadows appeared in her chest x-ray which were finally confirmed to be metastases in February 1974. Clinical examination of the abdomen at that time was normal. The LAP was within normal limits throughout this illness (Fig. 5) .
The illustrative cases and the data in the Resection of the primary tumour when there were well established hepatic metastases had little or no effect on the level of CEA (Fig. 6) , contrasting with the fall of the CEA level after successful resection of localized primary tumour (Laurence et al., 1972) . The changes encountered in hepatic metastases can be grouped into 3 phases: Initially, there may be no change in any of the markers; this is observed in some patients found to have small metastases in the liver at laparotomy. This is followed by a progressive rise in the CEA and GGT levels in the blood without any disturbance of the other liver function tests (AP, LAP and the transaminases). Finally, the classic liver function tests become positive, by which time the CEA levels may be well over 1000 ng/ml and can reach much higher values, the highest recorded in this series being 250,000 ng/ml. This sample has been shown to be immunologically identical to CEA by immunodiffusion; on a simple Ouchterlony plate it gave a line of complete identity with authentic colonic CEA against monospecific anti-colonic CEA. On the other hand, the growth of metastatic tumour in sites other than the liver, i.e. peritoneum, pelvic organs or lung, was associated1 with an increase of the CEA and GGT levels, usually at a slower rate than seen in hepatic metastases and less likely to cause a disturbance in the AP or LAP.
DIJSCUSSION
At present the adjuncts that can be used in association with CEA for monitoring colorectal cancer are all nonspecific. Gamma glutamyl transpeptidase is well known to be a very sensitive indicator of liver disease but is liable to be elevated in a variety of other diseases not directly affecting the liver (Boone, Routh and Schrantz, 1974 (Mackay et al., 1974) . There is a great variety of serum enzymes that have been reported to be increased in cancer (see review by Schwartz, 1973) . Some are well known to be elevated in liver disease and form the basis of standard liver function tests. It seems that alkaline phosphatase and leucine aminopeptidase are raised in cases of well established metastases. Preliminary studies of 5' nucleotidase (unpublished results) suggest that as a monitor of colorectal cancer, its sensitivity lies between GGT and AP. The use of a battery of enzymes enables the progress of hepatic metastases to be followed and gives the clinician an indication of the extent of the disease. The wide variation in the level of CEA produced in hepatic metastases suggests that this test alone does not give much indication as to how the metastases are progressing. The reason for the very high levels of CEA in the blood in some patients is unknown; it could be due to decreased degradation of CEA or there is the possibility that the hepatic cells may themselves be contributing to the plasma CEA as the result of an inductive stimulus for CEA production receiVed from contiguous cancer cells.
Such a battery of tests may be very important when attempting to follow the response to chemotherapy and when trying to sort out the direct effects of the agent upon an enzyme system compared with the effects resulting from an improvement of liver function.
There is still a need for improved methods for detecting metastases not involving the liver. One possibility lies in detecting enzyme markers that are a characteristic feature of the primary tumour, in the hope that they might return when the patient develops a metastasis. Muramidase (lysozyme) may act in this way; our present data suggest that about 5000 of the patients with primary tumours have elevated serum muramidase levels which fall to normal when the tumour is excised .
Elevations of muramidase are also seen in some patients with hepatic or pelvic metastases; as yet we are uncertain whether such patients had a raised muramidase at the time they first presented with a primary.
The data from the surveillance study indicate that GGT and standard LFTs have a place with CEA in the monitoring system. LFTs should be carried out if the GGT exceeds 100 i.u./l or the CEA 500 ng/ml. There is still a pressing need to obtain an improved test system for the detection and monitoring of early pelvic and peritoneal tumours as these are often the target for adjuvant chemotherapy for minimal residual disease.
